Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
MSON's Cash-to-Debt is ranked higher than
100% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. MSON: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MSON' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: 3.5 Max: No Debt
Current: No Debt
Equity-to-Asset 0.89
MSON's Equity-to-Asset is ranked higher than
92% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. MSON: 0.89 )
Ranked among companies with meaningful Equity-to-Asset only.
MSON' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.14  Med: 0.75 Max: 0.93
Current: 0.89
0.14
0.93
Interest Coverage No Debt
MSON's Interest Coverage is ranked higher than
99% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 86.37 vs. MSON: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MSON' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 16.80
Beneish M-Score: -3.19
WACC vs ROIC
0.79%
-31.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -24.11
MSON's Operating Margin % is ranked lower than
69% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. MSON: -24.11 )
Ranked among companies with meaningful Operating Margin % only.
MSON' s Operating Margin % Range Over the Past 10 Years
Min: -35.87  Med: -18.51 Max: -4.22
Current: -24.11
-35.87
-4.22
Net Margin % -6.72
MSON's Net Margin % is ranked lower than
62% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. MSON: -6.72 )
Ranked among companies with meaningful Net Margin % only.
MSON' s Net Margin % Range Over the Past 10 Years
Min: -28.56  Med: -4.13 Max: 25.09
Current: -6.72
-28.56
25.09
ROE % -6.77
MSON's ROE % is ranked lower than
60% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. MSON: -6.77 )
Ranked among companies with meaningful ROE % only.
MSON' s ROE % Range Over the Past 10 Years
Min: -21.42  Med: -5.53 Max: 27.78
Current: -6.77
-21.42
27.78
ROA % -5.98
MSON's ROA % is ranked lower than
58% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. MSON: -5.98 )
Ranked among companies with meaningful ROA % only.
MSON' s ROA % Range Over the Past 10 Years
Min: -18.21  Med: -4.01 Max: 24.23
Current: -5.98
-18.21
24.23
ROC (Joel Greenblatt) % -65.74
MSON's ROC (Joel Greenblatt) % is ranked lower than
66% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. MSON: -65.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MSON' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -65.74  Med: -31.07 Max: -7.66
Current: -65.74
-65.74
-7.66
3-Year Revenue Growth Rate 12.20
MSON's 3-Year Revenue Growth Rate is ranked higher than
74% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. MSON: 12.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MSON' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35.3  Med: 5.9 Max: 36.3
Current: 12.2
-35.3
36.3
3-Year EBITDA Growth Rate 21.00
MSON's 3-Year EBITDA Growth Rate is ranked higher than
71% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. MSON: 21.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MSON' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -60.6  Med: -18.7 Max: 80.4
Current: 21
-60.6
80.4
3-Year EPS without NRI Growth Rate -24.80
MSON's 3-Year EPS without NRI Growth Rate is ranked lower than
80% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. MSON: -24.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MSON' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -53.6  Med: -9.9 Max: 169.2
Current: -24.8
-53.6
169.2
GuruFocus has detected 2 Warning Signs with Misonix Inc $MSON.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MSON's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

MSON Guru Trades in Q2 2016

Jim Simons 171,000 sh (+3.01%)
» More
Q3 2016

MSON Guru Trades in Q3 2016

Jim Simons 173,500 sh (+1.46%)
» More
Q4 2016

MSON Guru Trades in Q4 2016

Jim Simons 168,900 sh (-2.65%)
» More
Q1 2017

MSON Guru Trades in Q1 2017

Jim Simons 166,600 sh (-1.36%)
» More
» Details

Insider Trades

Latest Guru Trades with MSON

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare:NAS:IRMD, NAS:NVTR, NAS:CGNT, NAS:EDAP, NAS:SPAN, NAS:IRIX, NAS:DRAD, OTCPK:PHMZF, NAS:NVCN, NAS:EYES, NAS:ACRX, OTCPK:TITXF, NAS:SPNE, NAS:SRTS, OTCPK:IVOB, NAS:PAVM, OTCPK:BTCY, OTCPK:BLOZF, OTCPK:AVMXF, OTCPK:DMTRF » details
Traded in other countries:MX9.Germany,
Headquarter Location:USA
Misonix Inc designs, manufactures, markets and develops minimally invasive ultrasonic surgical device products. Its products include the BoneScalpel surgical system, the SonaStar Surgical Aspirator and the SonicOne Wound Cleansing and Debridement System.

Misonix Inc a New York corporation organized in 1959. The Company designs, manufactures, markets and develops minimally invasive ultrasonic medical device products. These products include the BoneScalpel cutting system which is used among other things for surgical procedures of the spine and on Maxillofacial procedures, the SonaStar Surgical Aspirator which is used to emulsify and remove soft and hard tumors, the SonicOne Wound Cleansing and Debridement System which offers tissue specific debridement and cleansing of wounds for effective removal of devitalized tissue and fibrin deposits while sparing viable cells. and the AutoSonix ultrasound cutting and coagulating system which is distributed and marketed for Misonix through Mentor Corporation, a subsidiary of Johnson & Johnson. The Companys main competitors are Medtronic, Anspach, Johnson & Johnson, Integra Life Sciences, Inc., Söering, Stryker Corporation and Smith and Nephew. The Companys medical device products are subject to the regulatory requirements of the U.S. Food and Drug Administration.

Top Ranked Articles about Misonix Inc

Misonix, Inc. To Report Third Quarter Fiscal Year 2017 Financial Results On Tuesday, May 2, 2017
Interim CEO Invests in Misonix Insider acquires 761,469 shares
Stavros Vizirgianakis (Insider Trades), interim CEO and 10% owner of Misonix Inc. (MSON), acquired 761,469 shares in the company on Oct. 25. The price per share was $5.25 for a total transaction of $3,997,712. Read more...

Ratios

vs
industry
vs
history
PB Ratio 3.28
MSON's PB Ratio is ranked lower than
59% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. MSON: 3.28 )
Ranked among companies with meaningful PB Ratio only.
MSON' s PB Ratio Range Over the Past 10 Years
Min: 0.26  Med: 1.54 Max: 5.88
Current: 3.28
0.26
5.88
PS Ratio 3.37
MSON's PS Ratio is ranked lower than
58% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. MSON: 3.37 )
Ranked among companies with meaningful PS Ratio only.
MSON' s PS Ratio Range Over the Past 10 Years
Min: 0.12  Med: 1.3 Max: 5.7
Current: 3.37
0.12
5.7
EV-to-EBIT -13.56
MSON's EV-to-EBIT is ranked lower than
99.99% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. MSON: -13.56 )
Ranked among companies with meaningful EV-to-EBIT only.
MSON' s EV-to-EBIT Range Over the Past 10 Years
Min: -212.1  Med: -11.9 Max: -0.7
Current: -13.56
-212.1
-0.7
EV-to-EBITDA -16.60
MSON's EV-to-EBITDA is ranked lower than
99.99% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. MSON: -16.60 )
Ranked among companies with meaningful EV-to-EBITDA only.
MSON' s EV-to-EBITDA Range Over the Past 10 Years
Min: -809.8  Med: -9.6 Max: 141.6
Current: -16.6
-809.8
141.6
Current Ratio 6.36
MSON's Current Ratio is ranked higher than
87% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. MSON: 6.36 )
Ranked among companies with meaningful Current Ratio only.
MSON' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 3.89 Max: 13.67
Current: 6.36
0.83
13.67
Quick Ratio 4.92
MSON's Quick Ratio is ranked higher than
84% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. MSON: 4.92 )
Ranked among companies with meaningful Quick Ratio only.
MSON' s Quick Ratio Range Over the Past 10 Years
Min: 0.5  Med: 2.96 Max: 12.83
Current: 4.92
0.5
12.83
Days Inventory 248.46
MSON's Days Inventory is ranked lower than
80% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. MSON: 248.46 )
Ranked among companies with meaningful Days Inventory only.
MSON' s Days Inventory Range Over the Past 10 Years
Min: 170.08  Med: 209.37 Max: 397.65
Current: 248.46
170.08
397.65
Days Sales Outstanding 61.69
MSON's Days Sales Outstanding is ranked higher than
66% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. MSON: 61.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
MSON' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.1  Med: 69.65 Max: 94.8
Current: 61.69
61.1
94.8
Days Payable 66.46
MSON's Days Payable is ranked higher than
54% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. MSON: 66.46 )
Ranked among companies with meaningful Days Payable only.
MSON' s Days Payable Range Over the Past 10 Years
Min: 33.6  Med: 74.13 Max: 108.56
Current: 66.46
33.6
108.56

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.90
MSON's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. MSON: -2.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MSON' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -49.2  Med: -1.3 Max: 11.4
Current: -2.9
-49.2
11.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.87
MSON's Price-to-Net-Cash is ranked higher than
60% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 17.13 vs. MSON: 10.87 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MSON' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 10.35 Max: 86.83
Current: 10.87
0
86.83
Price-to-Net-Current-Asset-Value 5.00
MSON's Price-to-Net-Current-Asset-Value is ranked higher than
56% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 6.88 vs. MSON: 5.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MSON' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 2.76 Max: 8.6
Current: 5
0
8.6
Price-to-Tangible-Book 3.62
MSON's Price-to-Tangible-Book is ranked lower than
51% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. MSON: 3.62 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MSON' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.43  Med: 1.99 Max: 8.02
Current: 3.62
0.43
8.02
Price-to-Intrinsic-Value-Projected-FCF 5.95
MSON's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
80% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. MSON: 5.95 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MSON' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 2.21 Max: 247.4
Current: 5.95
0
247.4
Price-to-Median-PS-Value 2.59
MSON's Price-to-Median-PS-Value is ranked lower than
95% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. MSON: 2.59 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MSON' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.93 Max: 3.83
Current: 2.59
0
3.83
Earnings Yield (Greenblatt) % -7.36
MSON's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. MSON: -7.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MSON' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -8.58  Med: 0 Max: 83.3
Current: -7.36
-8.58
83.3

More Statistics

Revenue (TTM) (Mil) $25.78
EPS (TTM) $ -0.22
Beta-0.24
Short Percentage of Float0.67%
52-Week Range $4.35 - 12.00
Shares Outstanding (Mil)9.02
» More Articles for MSON

Headlines

Articles On GuruFocus.com
Misonix, Inc. To Report Third Quarter Fiscal Year 2017 Financial Results On Tuesday, May 2, 2017 Apr 26 2017 
Insiders Sell MasterCard, Microsoft Oct 28 2016 
Interim CEO Invests in Misonix Oct 27 2016 
Weekly CFO Buys Highlight May 19 2013 
MISONIX Inc. (MSON) CEO Michael A Jr Mcmanus buys 5,000 Shares Dec 01 2009 
MISONIX Inc. Reports Operating Results (10-Q) Nov 16 2009 
MISONIX Inc. Reports Operating Results (10-K) Sep 28 2009 
MISONIX Inc. Reports Operating Results (10-Q) May 12 2009 

More From Other Websites
ETFs with exposure to Misonix, Inc. : May 19, 2017 May 19 2017
Edited Transcript of MSON earnings conference call or presentation 2-May-17 8:30pm GMT May 05 2017
Misonix, Inc. :MSON-US: Earnings Analysis: Q3, 2017 By the Numbers : May 5, 2017 May 05 2017
Misonix reports 3Q loss May 02 2017
Misonix Reports Third Quarter Fiscal Year 2017 Financial Results May 02 2017
Investor Network: MISONIX INC to Host Earnings Call May 02 2017
Misonix, Inc. To Report Third Quarter Fiscal Year 2017 Financial Results On Tuesday, May 2, 2017 Apr 26 2017
ETFs with exposure to Misonix, Inc. : April 5, 2017 Apr 05 2017
Edited Transcript of MSON earnings conference call or presentation 14-Mar-17 1:00pm GMT Mar 30 2017
Misonix, Inc. :MSON-US: Earnings Analysis: Q2, 2017 By the Numbers : March 17, 2017 Mar 17 2017
Misonix, Inc. To Review Financial Results for First Half of Fiscal Year 2017 On Tuesday, March 14,... Mar 13 2017
Misonix Files Forms 10-Q for First and Second Quarters of Fiscal 2017 Mar 13 2017
Misonix, Inc. Enters into Exclusive Chinese Distribution Agreement for BoneScalpel Mar 07 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of... Feb 17 2017
Misonix Reports Receipt of Deficiency Letter from The Nasdaq Stock Market LLC Feb 13 2017
Misonix Files Form 10-K Announcing Fiscal 2016 Financial Results Feb 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat